Conference Coverage

Long-acting basal insulin controls HbA1c as well as glargine

Publish date: September 16, 2015

 

AT EASD 2015

References

Eli Lilly & Co. funded the study. Dr. Garg has received research funding from the company.

msullivan@frontlinemedcom.com

Pages

Recommended Reading

VIDEO: Newer type 2 diabetes drugs pose no significant heart failure risk
MDedge Internal Medicine
Finerenone cuts albuminuria in diabetic nephropathy
MDedge Internal Medicine
Diabetes prevalence rising, especially in black, Asian, and Hispanic populations
MDedge Internal Medicine
HbA1c aids prediction of atherosclerotic CVD
MDedge Internal Medicine
High-calorie American diet causes insulin resistance within days
MDedge Internal Medicine
So much sugar in long-term care
MDedge Internal Medicine
FDA issues revised warning for adverse effects associated with canagliflozin
MDedge Internal Medicine
ESC: Further data indicate no excess heart failure risk with lixisenatide or sitagliptin
MDedge Internal Medicine
EASD: High HbA1c linked to elevated dementia risk in patients with 2DM
MDedge Internal Medicine
EASD: Intranasal glucagon reverses hypoglycemia in children and adolescents
MDedge Internal Medicine